COSMOS

COmedication Study Assessing Mono- and cOmbination Therapy With an Active Drug inteStinal Gel

Brief summary

The purpose of this study is to evaluate treatment of advanced Parkinson's Disease (PD) patients on an active drug intestinal gel monotherapy in a routine clinical setting.

Observational study

Status:
Completed
Conditions:
Parkinson's Disease (PD)
Enrollment:
412 patients
Protocol ID:
P16-831
Observational model:
Cohort
Time perspective:
Cross-Sectional

Would you like to know more about this trial?

Yes, please contact me

Eligibility criteria

Participant attributes:
Male and Female

Age:

18 Years and older.

Inclusion Criteria:

- Participants diagnosed with APD and on LCIG treatment for at least 12 months

- Participant must have been on continuous LCIG treatment for at least 80% of days in
the preceding year

- Participants must be treated by the same physician (principal investigator or
co-investigator) since the initiation of LCIG treatment

Exclusion Criteria:

- Participation in a concurrent or a previous interventional clinical trial during which
the participant was on LCIG therapy

- Lack of motivation or insufficient language skills to complete the study
questionnaires

All the cities where the clinical studies are located

Calgary - T2N 4Z6
Ottawa - K1Y 4E9
Toronto - M5T 2S8
Lévis - G6W 0M5

Alberta

Quebec